-
公开(公告)号：US20210246468A1
公开(公告)日：2021-08-12
申请号：US16973630
申请日：2019-06-11
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia AMMENDOLA , Stefania CAPONE , Stefano COLLOCA , Antonella FOLGORI , Rosella MERONE
Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
-
公开(公告)号：US20160000904A1
公开(公告)日：2016-01-07
申请号：US14770510
申请日：2014-03-14
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano COLLOCA , Riccardo CORTESE , Antonella FOLGORI , Alfredo NICOSIA
IPC: A61K39/29 , C12N15/86 , C07K14/74 , C12N7/00 , C07K14/005
CPC classification number: A61K39/29 , A61K39/00 , A61K2039/53 , C07K14/005 , C07K14/70539 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/24041 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
Abstract translation: 本申请涉及包含编码抗原蛋白和不变链的核酸构建体的痘病毒载体的新型施用方案。 特别地，公开了使用所述痘病毒载体引发或增强免疫应答。
-
公开(公告)号：US20210198321A1
公开(公告)日：2021-07-01
申请号：US16770963
申请日：2018-12-14
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefania CAPONE , Antonella FOLGORI , Armin LAHM , Benjamin WIZEL
IPC: C07K14/005 , C12N7/00 , A61K39/245
Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.
-
公开(公告)号：US20180125968A1
公开(公告)日：2018-05-10
申请号：US15848100
申请日：2017-12-20
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor： Stefano COLLOCA , Riccardo CORTESE , Antonella FOLGORI , Alfredo NICOSIA
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
Patent Agency Ranking
公开(公告)号：US20190338014A1
公开(公告)日：2019-11-07
申请号：US16327575
申请日：2017-08-23
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA , UNIVERSITY OF COPENHAGEN
Inventor： Maria Rosaria BASSI , Riccardo CORTESE , Anna Morena D'ALISE , Antonella FOLGORI , Peter Johannes HOLST , Alfredo NICOSIA
Abstract: The present application provides inter alia a fusion protein comprising a polypeptide wherein the polypeptide consists of a fragment of invariant chain which is operably linked to an antigenic sequence and wherein the fragment of invariant chain consists of a portion of residues 17-97 of SEQ ID NO: 1, wherein the portion comprises at least 5 contiguous residues from residues 77-92 of SEQ ID NO: 1.
-
公开(公告)号：US20240076318A1
公开(公告)日：2024-03-07
申请号：US18358350
申请日：2023-07-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefania CAPONE , Antonella FOLGORI , Armin LAHM , Benjamin WIZEL
IPC: C07K14/005 , A61K39/245 , C12N7/00
CPC classification number: C07K14/005 , A61K39/245 , C12N7/00 , A61K2039/70
Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.
-
公开(公告)号：US20220275397A1
公开(公告)日：2022-09-01
申请号：US17742221
申请日：2022-05-11
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia AMMENDOLA , Stefania CAPONE , Stefano COLLOCA , Antonella FOLGORI , Rossella MERONE
Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
-
公开(公告)号：US20200164061A1
公开(公告)日：2020-05-28
申请号：US16782268
申请日：2020-02-05
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano COLLOCA , Riccardo CORTESE , Antonella FOLGORI , Alfredo NICOSIA
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
公开(公告)号：US20170333550A1
公开(公告)日：2017-11-23
申请号：US15461978
申请日：2017-03-17
Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
Inventor： Stefano COLLOCA , Riccardo CORTESE , Antonella FOLGORI , Alfredo NICOSIA
CPC classification number: A61K39/29 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/6031 , C12N7/00 , C12N15/86 , C12N2710/10334 , C12N2710/10343 , C12N2710/24034 , C12N2710/24043 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
